Incident choroidal neovascularization in fellow eyes of patients with unilateral subfoveal choroidal neovascularization secondary to age-related macular degeneration: SST report no. 20 from the Submacular Surgery Trials Research Group

Archives of Ophthalmology

Volumn 125, Issue 10, 2007, Pages 1323-1330

  Solomon, Sharon D ^a   Jefferys, Joan L ^a   Hawkins, Barbara S ^a   Bressler, Neil M ^a   Bressler, Susan B ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGRAPHY; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; FLUORESCENCE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; PATIENT ASSESSMENT; PRIORITY JOURNAL; QUALITY CONTROL; RETINA MACULA AGE RELATED DEGENERATION; RISK ASSESSMENT; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

AGED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; INCIDENCE; MACULAR DEGENERATION; MALE; RISK FACTORS; UNITED STATES; VISUAL ACUITY;

EID: 35349011715     PISSN: 00039950     EISSN: 00039950     Source Type: Journal    
DOI: 10.1001/archopht.125.10.1323     Document Type: Article

References (20)

1. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report No. 11. Arch Ophthalmol. 2003;121(11):1621-1624.
2. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1419-1431.
3. Brown DM, Kaiser PK, MichelsM, et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355(14):1432-1444.
4. The Choroidal Neovascularization Prevention Trial Research Group. Choroidal neovascularization in the Choroidal Neovascularization Prevention Trial. Ophthalmology. 1998;105(8):1364-1372.
5. Chang B, Yannuzzi LA, Ladas ID, Guyer DR, Slakter JS, Sorenson JA. Choroidal neovascularization in second eyes of patients with unilateral exudative age-related macular degeneration. Ophthalmology. 1995;102(9):1380-1386.
6. Macular Photocoagulation Study Group. Five-year follow-up of fellow eyes of patients with age-related macular degeneration and unilateral extrafoveal choroidal neovascularization. Arch Ophthalmol. 1993;111(9):1189-1199.
7. Macular Photocoagulation Study Group. Risk factors for choroidal neovascularization in the second eye of patients with juxtafoveal or subfoveal choroidal neovascularization secondary to age-related macular degeneration. Arch Ophthalmol. 1997;115(6):741-747.
8. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report No. 8. Arch Ophthalmol. 2001;119(10):1417-1436.
9. Submacular Surgery Trials (SST) Research Group. Surgery for subfoveal choroidal neovascularization in age-related macular degeneration: ophthalmic findings: SST report No. 11. Ophthalmology. 2004;111(11):1967-1980.
10. Submacular Surgery Trials (SST) Research Group. Surgery for hemorrhagic choroidal neovascular lesions of age-related macular degeneration: ophthalmic findings: SST report No. 13. Ophthalmology. 2004;111(11):1993-2006.
11. Fleiss JL. Statistical Methods for Rates and Proportions. 2nd ed. New York, NY: John Wiley & Sons; 1981:217-225.
12. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
13. Pearson K. On the criterion that a given system of deviations from the probable in the case of a correlated system of variables is such that it can be reasonably supposed to have arisen from random sampling. Philos Mag. 1900;50(5):157-175.
14. Armitage P, Berry G. Statistical Methods in Medical Research. 2nd ed. Boston, MA: Blackwell Scientific Publications Inc; 1987:372-374.
15. McNemar Q. Note on the sampling error of the difference between correlated proportions or percentages. Psychometrika. 1947;12:153-157.
16. Gragoudas ES, Adamis AP, Cunningham ET, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med. 2004;351(27):2805-2816.
17. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials, TAP report 1. Arch Ophthalmol. 1999;117(10):1329-1345.
18. Stevens TS, Bressler NM, Maguire MG, et al. Occult choroidal neovascularization in age-related macular degeneration: a natural history study of morphologic changes. Arch Ophthalmol. 1997;115(3):345-350.
19. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy and Verteporfin in Photodynamic Therapy Study Groups. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration: TAP and VIP report No. 1. Am J Ophthalmol. 2003;136(3):407-418.
20. Macular Photocoagulation Study Group. Visual outcome after laser photocoagulation for subfoveal choroidal neovascularization secondary to age-related macular degeneration: the influence of initial lesion size and initial visual acuity. Arch Ophthalmol. 1994;112(4):480-488.